CSL Seqirus has confirmed that its intravenous iron therapy, Ferinject (ferric carboxymaltose), is now indicated in Australia for the treatment of iron deficiency anaemia in children aged one to 13 years when oral iron preparations are ineffective or cannot be used.
Ferinject is currently approved for use in adults and adolescents aged 14 years and older for iron deficiency.
The new approval means eligible patients 13 and under can now receive Ferinject following the diagnosis of iron deficiency anaemia based on laboratory tests in patients who meet the indication.
In Australia, it has been estimated that approximately 8% of pre-school children, 12% of pregnant women and 15% of non-pregnant women are living with anaemia.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Feb 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Feb 24
